Market Overview

Janney: Amicus Therapeutics Has Significant Upside From Gene Therapy Pipeline

Share:
Janney: Amicus Therapeutics Has Significant Upside From Gene Therapy Pipeline

Amicus Therapeutics, Inc. (NASDAQ: FOLD) has an extensive portfolio of novel therapies for rare diseases with a focus on lysosomal storage disorders, according to Janney Montgomery Scott. 

The Analyst

Janney's Yun Zhong initiated coverage of Amicus Therapeutics with a Buy rating and $20 fair value estimate.

The Thesis

Galafold, a next-gen enzyme replacement therapy, is well-positioned to gain significant share of the expanding Fabry disease market, Zhong said in the Friday initiation note. 

While global ERT sales reached nearly $1.5 billion in 2018, a large number of patients are not receiving treatment — mainly due to the requirement of biweekly IV infusions, the analyst said. Against this backdrop, Galafold offers a highly favorable alternative treatment, as it offers oral dosing with comparable efficacy, he said. 

A large number of undiagnosed or misdiagnosed Fabry patients carry mutations, Zhong said, adding that such patients will be more amenable to Galafold treatment. 

Expressing optimism regarding the therapy's rapid penetration due to increased disease awareness and improved diagnostics, Zhong said that Amicus' $500-million estimate could prove highly conservative.

With the Celenex acquisition, Amicus gained access to one the broadest gene therapy pipelines in the industry, the analyst said. The acquisition, along with the UPenn collaboration and the company’s expertise, could help Amicus build a platform that will support its exponential growth in the coming years, he said. 

The company has another ERT in pivotal Phase III clinical development for Pompe disease. Given the strong Galafold launch trend and encouraging Pompe data to date, there seems to be limited downside risk for Amicus, according to Janney. 

Price Action

Shares of Amicus rose slightly to trade at $14.20 on Friday morning.

Related Links: 

Benzinga's Top Upgrades, Downgrades For April 5, 2019

81 Biggest Movers From Friday

Latest Ratings for FOLD

DateFirmActionFromTo
Apr 2019Initiates Coverage OnBuy
Jan 2019Initiates Coverage OnOverweight
Jan 2019UpgradesNeutralBuy

View More Analyst Ratings for FOLD
View the Latest Analyst Ratings

Posted-In: Janney Montgomery Scott Yun ZhongAnalyst Color Biotech Price Target Initiation Analyst Ratings General Best of Benzinga

 

Related Articles (FOLD)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
ELMDDougherty & Co.Initiates Coverage On12.0
MRNSCantor FitzgeraldAssumes7.0
MNRLCapital One FinancialInitiates Coverage On23.0
SONVertical GroupUpgrades
UNPMorgan StanleyMaintains136.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

40 Stocks Moving In Friday's Mid-Day Session

Benzinga CEO Chats About The Cannabis Media Space On Green Rush Podcast